Injection drug use cessation and use of North America's first medically supervised safer injecting facility

Drug and Alcohol Dependence

Volumn 113, Issue 2-3, 2011, Pages 172-176

  DeBeck, Kora ^a   Kerr, Thomas ^a,b   Bird, Lorna ^c   Zhang, Ruth ^a   Marsh, David ^b,d,e   Tyndall, Mark ^a,b   Montaner, Julio ^a,b   Wood, Evan ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Western Aboriginal Harm Reduction Society   (Canada)

^d Providence Health Care   (Canada)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Aboriginal ancestry; Addiction treatment; Injection cessation; Injection drug use; Supervised injection

Indexed keywords

METHADONE;

ABORIGINE; ADULT; ARTICLE; CANADA; COUNSELING; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG WITHDRAWAL; FEMALE; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SUPERVISED INJECTING FACILITY;

ADULT; CANADA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 78651485509     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.07.023     Document Type: Article

References (32)

1. Christie T., Wood E., Schechter M., O'Shaughnessy M. A comparison of the new Federal Guidelines regulating supervised injection site research in Canada and the Tri-Council Policy Statement on Ethical Conduct for Research Involving Human Subjects. Int. J. Drug Policy 2004, 15:66-73.
2. DeBeck K., Kerr T., Li K., Milloy M.J., Montaner J., Wood E. Incarceration and drug use patterns among a cohort of injection drug users. Addiction 2009, 104:69-76.
3. Doherty M.C., Garfein R.S., Vlahov D., Junge B., Rathouz P.J., Galai N., Anthony J.C., Beilenson P. Discarded needles do not increase soon after the opening of a needle exchange program. Am. J. Epidemiol. 1997, 145:730-737.
4. Dolan K., Kimber J., Fry C., McDonald D., Fitzgerald J., Trautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug Alcohol Rev. 2000, 19:337-346.
5. Evans J.L., Hahn J.A., Lum P.J., Stein E.S., Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend. 2009, 101:152-157.
6. Galai N., Safaeian M., Vlahov D., Bolotin A., Celentano D. Longitudinal patterns of drug injection behavior in the ALIVE Study Cohort, 1988-2000: description and determinants. Am. J. Epidemiol. 2003, 158:695.
7. Gandey A. US slams Canada over Vancouver's new drug injection site. Can. Med. Assoc. J. 2003, 169:1063.
8. Garfield J., Drucker E. Fatal overdose trends in major US cities: 1990-1997. Addict. Res. Theor. 2001, 9:425-436.
9. Grund J.P., Blanken P., Adriaans N.F., Kaplan C.D., Barendregt C., Meeuwsen M. Reaching the unreached: targeting hidden IDU populations with clean needles via known user groups. J. Psychoactive Drugs 1992, 24:41-47.
10. International Narcotics Control Board, March 5, 2008. Report of the International Narcotics Control Board for 2007. (accessed 04.07.10). http://www.incb.org/pdf/annual-report/2007/en/annual-report-2007.pdf.
11. Jones D. Injection site gets 16-month extension. Can. Med. Assoc. J. 2006, 175:859.
12. Joseph Rowntree Foundation The Report of the Independent Working Group on Drug Consumption Rooms 2006, Joseph Rowntree Foundation, York, (accessed 12.12.09). http://www.jrf.org.uk/sites/files/jrf/9781859354711.pdf.
13. Karon J.M., Fleming P.L., Steketee R.W., De Cock K.M. HIV in the United States at the turn of the century: an epidemic in transition. Am. J. Public Health 2001, 91:1060-1068.
14. Kerr T., Tyndall M., Li K., Montaner J., Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316-318.
15. Kimber J., Dolan K., Van Beek I., Hendrich D., Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev. 2003, 22:227-233.
16. Kimber J., Mattick R.P., Kaldor J., van Beek I., Gilmour S., Rance J.A. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. Drug Alcohol Rev. 2008, 27:602-612.
17. Lurie P. Invited commentary: le mystere de Montreal. Am. J. Epidemiol. 1997, 146:1003-1006. (discussion 1007-10).
18. MSIC Evaluation Committee Final report of the evaluation of the Sydney medically supervised injecting centre 2003, (accessed 27.03.10). http://www.sydneymsic.com/Bginfo.htm.
19. Neaigus A., Friedman S.R., Curtis R., Des Jarlais D.C., Furst R.T., Jose B., Mota P., Stepherson B., Sufian M., Ward T. The relevance of drug injectors' social and risk networks for understanding and preventing HIV infection. Soc. Sci. Med. 1994, 38:67-78.
20. Shah N.G., Galai N., Celentano D.D., Vlahov D., Strathdee S.A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000. Drug Alcohol Depend. 2006, 83:147-156.
21. Tyndall M., Kerr T., Zhang R., King E., Montaner J., Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug Alcohol Depend. 2006, 83:193-198.
22. Wood E., Kerr T., Montaner J.S., Strathdee S.A., Wodak A., Hankins C.A., Schechter M.T., Tyndall M.W. Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect. Dis. 2004, 4:301-306.
23. Wood E., Kerr T., Small W., Li K., Marsh D., Montaner J., Tyndall M. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Can. Med. Assoc. J. 2004, 171:731-734.
24. Wood E., Kerr T., Lloyd-Smith E., Buchner C., Marsh D., Montaner J., Tyndall M. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct. J. 2004, 1.
25. Wood E., Li K., Palepu A., Marsh D.C., Schechter M.T., Hogg R.S., Montaner G.J.S., Kerr T. Sociodemographic disparities in access to addiction treatment a among a cohort of Vancouver injection drug users. Subst. Use Misuse 2005, 40:1153-1167.
26. Wood E., Tyndall M.W., Li K., Lloyd-Smith E., Small W., Montaner J.S., Kerr T. Do supervised injecting facilities attract higher-risk injection drug users?. Am. J. Prev. Med. 2005, 29:126-130.
27. Wood E., Tyndall M.W., Zhang R., Stoltz J.A., Lai C., Montaner J.S., Kerr T. Attendance at supervised injecting facilities and use of detoxification services. N. Engl. J. Med. 2006, 354:2512-2514.
28. Wood E., Montaner J.S., Li K., Barney L., Tyndall M.W., Kerr T. Rate of methadone use among Aboriginal opioid injection drug users. Can. Med. Assoc. J. 2007, 177:37.
29. Wood E., Tyndall M.W., Zhang R., Montaner J.S., Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction 2007, 102:916-919.
30. Wood E., Kerr T., Tyndall M.W., Montaner J.S.G. The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int. J. Drug Policy 2008, 19:220-225.
31. Wright N.M., Tompkins C.N. Supervised injecting centres. Br. Med. J. 2004, 328:100-102.
32. Yamey G. UN condemns Australian plans for " safe injecting rooms" Br. Med. J. 2000, 320:667.